CARLSBAD - In support of global initiatives to advance molecular profiling in oncology, Thermo Fisher Scientific today announced the latest recipients of the Oncomine Clinical Research Grant and the. | April 18, 2023
Bourgoin Early Development Hub broadens offerings for oral solid dose formulations Thermo Fisher Scientific, the world leader in serving science, is adding early development work for oral solid dose
Thermo Fisher Scientific, the world leader in serving science, and Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage cell therapy company engineering advanced chimeric antigen receptor (CAR)-T cell therapies for solid tumors, today announced an update to our strategic collaboration to further the development of manufacturing processes for new cancer treatments.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and the University of California, San Francisco (UCSF), will accelerate advanced cell therapies for difficult to treat conditions, including cancer, rare diseases, and other illnesses, from a newly opened cGMP manufacturing facility .
27.03.2023 - Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and the University of California, San Francisco (UCSF), will accelerate advanced cell therapies for difficult to treat conditions, including cancer, rare diseases, and .